Fleming’s researchers have discovered that embryonic expression of Autotaxin, a secreted lysophospholipase D generating lysophosphatidic acid, is necessary for vascular branching morphogenesis and neural tube closure. [PubMed]

Computational miRNA target prediction remains one of the key means used to decipher the role of miRNAs in development and disease. In a recent review of Bioinformatics the team of A. Hatzigeorgiou from Fleming’s Institute of Molecular Oncology took it upon themselves to test the performance of the more popular miRNA target prediction algorithms out there and published what they found. The review was highlighted by the Epigenie newsletters. More info: Epigenie [Pubmed]

Introducing Biomedcode Hellas SA.
A spin off company of BSRC "Alexander Fleming" providing pre-clinical drug evaluation services to pharmaceutical companies using disease animal models.

The Center has established six core facilities to offer internal and external users direct access to its research infrastructures. The animal house facility, protein chemistry lab, expression profiling facility, transgenic facility, flow cytometry facility, innovation and enterprise unit, genotyping facility and BioIT unit are actively involved in collaborations with both academic and industrial partners.

The BSRC Fleming participates in a number of International programs. Such collaborations are of significant importance for the exchange and dissemination of knowledge and expertise as well as bring together major groups around the world for the study and therapy of human disease.